Olmesartan analysis | Other ARB analysis | |||||
---|---|---|---|---|---|---|
Olmesartan users (n=20) (%) | Matched controls (n=20) (%) | p Value | Other ARB users (n=20) (%) | Matched controls (n=20) (%) | p Value | |
Villous atrophy | 4/16 (25)* | 1/16 (6) | 0.33 | 1/14 (7)* | 2/19 (11) | 1.0 |
Crypt hyperplasia | 4/16 (25)* | 2/17 (12) | 0.40 | 3/14 (21)* | 4/18 (22) | 1.0 |
Mean maximum IEL count | 13.7 | 10.6 | 0.09 | 13.0 | 18.5 | 0.35 |
Generalised IEL increase | 4/20 (20) | 2/20 (10) | 0.67 | 2/20 (10) | 6/20 (30) | 0.24 |
Chronic inflammation | 5/20 (25) | 2/20 (10) | 0.40 | 7/20 (35) | 6/20 (30) | 1.0 |
Eosinophilia | 2/20 (10) | 0/20 (0) | 0.49 | 3/20 (15) | 2/20 (10) | 1.0 |
Neutrophilia | 8/20 (40) | 6/20 (30) | 0.74 | 4/20 (20) | 7/20 (35) | 0.48 |
Increased crypt apoptosis | 5/20(25) | 2/20 (10) | 0.40 | 6/20 (30) | 8/20 (40) | 0.74 |
One or more sprue-like features (architectural abnormalities, generalised increased IEL, chronic inflammation) | 10/20 (50) | 4/20 (20) | 0.10 | 9/20 (45) | 12/20 (60) | 0.34 |
*Villous atrophy and crypt hyperplasia was not evaluated in 4 olmesartan cases and in 6 ARB cases due to poor orientation.
ARB, angiotensin receptor blocker; IEL, intraepithelial lymphocyte.